timothy sykes logo
ImmunityBio’s Stock Surge: Opportunity or Risk? Thumbnail
G Google News

ImmunityBio’s Stock Surge: Opportunity or Risk?

JACK KELLOGG•UPDATED FEB. 28, 2025, 11:38 AM ET
Reviewed by Tim Sykesand Fact-checked by Ellis Hobbs

ImmunityBio Inc. is experiencing a boost in market sentiment, likely driven by recent positive developments from ImmunityBio’s flagship cancer vaccine, which is showing promise in clinical trials. On Friday, ImmunityBio Inc.’s stocks have been trading up by 9.62 percent.

Key Developments Shaping ImmunityBio’s Performance

  • Shares jumped over 17% after FDA approval for an expanded access program addressing a crucial bladder cancer drug shortage.
  • Recent FDA RMAT designation for Anktiva and CAR-NK further strengthens ImmunityBio’s position in advanced cancer therapies.
  • The marketing application for Anktiva in the UK reflects significant progress in global market expansion for ImmunityBio.
  • Collaboration with BeiGene in a Phase 3 trial highlights strategic partnerships to tackle complex cancer treatments.

Candlestick Chart

Live Update At 11:37:42 EST: On Friday, February 28, 2025 ImmunityBio Inc. stock [NASDAQ: IBRX] is trending up by 9.62%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Financial Overview of ImmunityBio

As millionaire penny stock trader and teacher Tim Sykes says, “There is always another play around the corner; don’t chase just because you feel FOMO.” In the fast-paced world of trading, the lure of immediate profits can often lead traders to make impulsive decisions based on fear of missing out. By remaining patient and disciplined, traders can avoid unnecessary risks and wait for the right opportunities to present themselves. It’s crucial to remember that the market continually offers new chances, but only a well-calculated approach can yield sustainable results.

ImmunityBio, Inc., with a recent stock surge, presents an intriguing case in the biotech industry. Looking closely at the financial metrics, it becomes clear why the market has reacted positively. On the surface, ImmunityBio’s revenue increased to $622k, but deeper insights reveal higher profitability challenges. The company reported a hefty $857.52M loss from continued operations, hinting at significant hurdles in its path. Despite generating a gross margin of 100%, signaling strong core product performance, the sky-high ebit margin of -5,728.5% indicates substantial operational inefficiencies. These figures, however, are not uncommon for research-heavy biotech firms focusing on breakthrough therapies.

More Breaking News

The story takes an interesting turn in the cash flow scenario. They had substantial cash returns from investments, highlighting smart allocation of resources. Purchasing long-term investments and property was strategically done yet impacted immediate cash flow negatively. At a glance, one might see the negative $98.76M operating cash flow and express concern. However, a deeper plunge into ImmunityBio’s deep research emphasis justifies these deficits, setting the stage for potential high returns on successful applications and trials. The company also holds $112.3M cash, boosting their capacity to sustain R&D efforts without immediate financing pressures.

Decoding Recent Stock Movements

Soaring and tumbling in stock values are typical for high-research, highly speculative companies like ImmunityBio. The recent approval by the FDA for an expanded access program to tackle a bladder cancer drug shortage has profusely boosted ImmunityBio’s stock. A generous 17% leap marked this event, draped with both opportunity and skepticism. Investors leaned on the promise of an indispensable product entering the market at a critical juncture. The key driver was the recombinant BCG securing an FDA nod amid a significant U.S. supply crunch, making ImmunityBio the torchbearer in this challenging market segment. Symbiotically, this approval doesn’t just grant them market entry; it establishes them as a preferred choice among healthcare providers, securing a prestigious competitive edge.

Parallelly, the Regenerative Medicine Advanced Therapy (RMAT) designation granted bolsters their position in oncology. This upswing in regulatory approvals augurs well for ImmunityBio’s pipeline, endorsing their innovative product’s efficacy as they charge ahead in cancer therapeutics.

Additionally, ImmunityBio’s marketing application approval in the UK for Anktiva aligns with their focused vision on expansion and diversification. The fusion of Anktiva with existing Bacillus Calmette-Guérin therapies in bladder cancer could potentially open doors to uncharted territories, enhancing revenue potential and establishing substantial international footholds. These strategic penetrations and expansions juxtapose their financial hardships, positioning ImmunityBio on a trajectory set to benefit investors willing to weather the stormy biotech seas.

Market Sentiments and Prospects

The sentiment surrounding ImmunityBio fluctuates akin to a pendulum swinging between optimism and caution. Changes in stock prices often mirror perceptions of future profitability intertwined with news, developments, and quirks of the biotech landscape.

Gains leveraged by significant regulatory nods and strategic partnerships convey more than immediate financial results. They encapsulate potential entering the fabric of the company’s intrinsic value. Partners like BeiGene elevate their collaborative efforts’ credibility, cementing their reputation among stakeholders while poising ImmunityBio as a leader in cancer therapeutics. Brand allies punctuate trader confidence even amidst the current ratio constraint of 2.7, signaling a liquid, albeit strained, position.

Yet, understanding ImmunityBio’s full picture entails grasping the inherent risk of trading in groundbreaking, albeit financially volatile, firms. Speculation, intrinsic to biotech, finds a home here. The gains, substantial if realized and consistent, court traders willing to embrace the rollercoaster journey that could heighten returns manifold upon therapeutic victories. As millionaire penny stock trader and teacher Tim Sykes says, “The goal is not to win every trade but to protect your capital and keep moving forward.” The forecast, albeit enthusiastic, should catalyze trader analysis beyond face value figures, exploring credibility and future vision realization. Given ImmunityBio’s pioneering position amidst evolving oncology solutions and partnerships, the prudent choice might lean toward patient analysis coupled with market-responsive agility.

In summary, ImmunityBio’s narrative is compelling, painted with vibrant hues of scientific progress and financial dips. Stock moves confirm the buzz yet remind stakeholders of the rigorous research path ahead to harvest returns. Whether traversing the cautious or hopeful route, ImmunityBio weaves a vital story in modern healthcare innovation—a tale of potential awaiting its protagonist’s final revelation.

This content is produced using automated systems designed to deliver timely stock news. All material is reviewed by our editorial team and is provided solely for informational and entertainment purposes. It does not constitute professional investment advice. For additional details, please refer to our [Terms of Service]

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”